Life Sciences Funding in Europe 2005 (Phase I) - Sources of Funding

 

USD 6,950

* Required Fields

USD 6,950

PAY BY INVOICE

Be the first to review this product

This research service examines and monitors life science funding trends in Europe. Funding analysis and challenges are discussed for United Kingdom, Germany and France and from the European Commission's perspective.

Table of Contents

Life Sciences Funding in Europe 2005 (Phase I) - Sources of Funding, Executive SummarySnapshot of the Life Sciences Funding in EuropeExecutive SummaryLife Sciences Funding in Europe 2005 (Phase I) - Sources of Funding, GlossaryGlossary of TermsGlossaryExchange RatesExchange RatesLife Sciences Funding in Europe 2005 (Phase I) - Sources of Funding, Project Background and MethodologyAssumptions and MethodologyResearch Scope and MethodologyLife Sciences Funding in Europe 2005 (Phase I) - Sources of Funding, European FundingFunding OverviewFunding Landscape - The European CommissionMarket Engineering MeasurementsMarket Engineering MeasurementsChallengesFunding ChallengesFunding AnalysisFunding ScenarioLife Sciences Funding in Europe 2005 (Phase I) - Sources of Funding, Funding Landscape in the United KingdomOverviewOverviewMarket Engineering MeasurementsMarket Engineering MeasurementsFunding AnalysisFunding ScenarioLife Sciences Funding in Europe 2005 (Phase I) - Sources of Funding, Funding Landscape in GermanyOverviewFunding Overview - GermanyMarket Engineering MeasurementsMarket Engineering MeasurementsFunding AnalysisFunding Scenario - GermanyLife Sciences Funding in Europe 2005 (Phase I) - Sources of Funding, Funding Scenario in FranceOverviewOverviewMarket Engineering MeasurementsMarket Engineering MeasurementsFunding AnalysisFunding ScenarioLife Sciences Funding in Europe 2005 (Phase I) - Sources of Funding, DSD for Life Science Funding in EuropePrivate Investment in BiotechnologyPrivate Investment in BiotechnologyNumber of Biotechnology CompaniesNumber of Biotechnology CompaniesGovernment R&D Investment in BiotechnologyGovernment R&D InvestmentPharmaceutical R&D ExpenditurePharmaceutical ExpenditurePharmaceutical R&D Expenditure as a per cent of Pharmaceutical MarketPharmaceutical Expenditure as a Percentage of Pharmaceutical Market




Keyword1

Keyword2

Keyword3

Related Research

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.